Horizon Pharma Investment $400 million 2.5% exchangeable senior notes issue

Overview:

• Horizon Pharma Investment has issued $400 million in exchangeable senior notes.
• The 2.5% notes are due in 2022 and were offered in a private placement to qualified institutional buyers pursuant to Rule 144A.
• Morgan Stanley, Jefferies, Cowen and Company, Guggenheim Securities and UBS are acting as joint bookrunning managers. JMP Securities and Avondale Partners are acting as co-managers.

Sam Duke - Editor